Momentum · Health Care
Strongest Health Care stocks by momentum.
As of 13 November 2026
Note of : Replimune's melanoma drug TUDRIQEV, first delivered on 6 October 2026, gives the shares a modest edge over the S&P 500 as early prescribing builds.
Research view: more likely to lead the S&P 500. Note of : Xeris Biopharma's shares are modestly more likely than not to beat the S&P 500 over three months because Recorlev sales rose 93% to $71.5 million in the third quarter and 2026 revenue guidance rose to $395–405 million.
Research view: more likely to lead the S&P 500. Note of : Liquidia Corporation's shares are modestly more likely to beat the S&P 500 because YUTREPIA sales rose 31% to $222.7 million in the third quarter with record October shipments; preliminary fourth-quarter sales, due in early January 2027, show whether that holds as PH-ILD use winds down.
Research view: more likely to lead the S&P 500. Note of : Viridian Therapeutics' shares are modestly more likely than not to beat the S&P 500: Lumvoa's $24.7 million first full quarter beat estimates and VRDN-008 data on 9 November 2026 added an autoimmune program.
Note of : Axogen's nerve-repair revenue grew 26.2% last quarter and a $754 million prostate market sits outside guidance, giving the shares a modest edge over the S&P 500; the Q4 2026 report settles whether revenue excluding BioCircuit reaches the…
Note of : Xencor's shares hold a modest edge over the S&P 500 on XmAb819's 45.5% confirmed response rate in advanced kidney cancer and cash funding into 2029.
Note of : Glaukos's iDose TR glaucoma implant and Epioxa keratoconus therapy lifted third-quarter 2026 sales 58% to $211.0 million, giving the shares a modest edge on a $1 billion 2027 outlook.
Note of : Teladoc Health's Q3 2026 beat and fast-growing BetterHelp insurance revenue give the shares a modest edge over the S&P 500. The refinancing of $1.0 billion of notes due June 2027 and the Q4 report settle whether the turnaround holds.
Note of : Ardent Health's cost-led hospital turnaround is running ahead of plan, with 2026 adjusted EBITDA guidance raised to $500–$535 million and Guggenheim and Stephens targets at $21; the 2027 outlook due with year-end results settles whether…
Research view: more likely to lag the S&P 500. Note of : OrthoPediatrics shares are more likely to lag the S&P 500 because the $33.67 close on 11 November 2026 sits above six of seven post-report analyst targets despite 19% sales growth.
Note of : Enovis Corporation's orthopedic turnaround passed its 5 November 2026 test with 4.6% organic growth, raised earnings guidance and a $200 million buyback.
Research view: more likely to lead the S&P 500. Oruka Therapeutics is modestly more likely to beat the S&P 500 over three months: its psoriasis antibody ORKA-001 cleared skin completely in 61% of high-dose patients against 0% on placebo, and the December 2026 52-week EVERLAST-A data show whether that clearance lasts a year without further dosing.
Note of : Disc Medicine's shares are modestly favoured to beat the S&P 500 over three months because bitopertin passed its Phase 3 APOLLO trial on 19 October 2026, answering the FDA's February rejection.
Research view: more likely to lag the S&P 500. Note of : Silence Therapeutics' shares trade just under Merck KGaA's $20-per-ADS cash takeover price, so they are more likely to lag the S&P 500 than lead it over three months.
Research view: more likely to lag the S&P 500. Note of : Surgery Partners' shares, at $26.58 on 12 November 2026, already price in more than HealthSpan Partners' $25.00 cash deal pays and are more likely to lag the S&P 500.
“3 months” is the stock's market price change over the last three months, not a FrontierPicks return. The "3 months" column is the stock's 3-month price move, one of the three inputs to that score, weighted 20% — not the ranking itself, so rows do not descend in it. “priced on a deal” marks a stock whose price tracks a pending takeover offer or other deal; a stock on a takeover offer is listed after the rest.
How this ranking works
Stocks are ordered by a composite momentum score — 1-month price trend 50%, 3-month trend 20% and acceleration 30% — computed arithmetically from daily closing prices, through the last completed session. No model sets the order. It is a screen of moves already made, not a buy list, rating or price target. A stock's research note can disagree with its momentum: where the note states a call, the row shows it as its research view.
Questions
- Which Health Care stocks have the strongest price momentum right now?
- As of 13 November 2026, the Health Care stocks with the strongest composite momentum score are REPL, PEPG, XERS and LQDA. Momentum measures moves already made; each name's research note gives its own view, which can differ.
- Why do some Health Care stocks have no research note?
- The daily scan scores 3,380 US stocks; this page lists this sector's names among the top 50. A research note exists only for the stocks the research covers; names without one are shown in grey.
- Where can I read the FrontierPicks research on these names?
- Each stock with a research note links to it: the dated thesis, the kill line that would prove it wrong and the next catalyst.
Related
As of 13 November 2026